AR124163A2 - Una composición de aripiprazol liofilizada - Google Patents
Una composición de aripiprazol liofilizadaInfo
- Publication number
- AR124163A2 AR124163A2 ARP210103281A ARP210103281A AR124163A2 AR 124163 A2 AR124163 A2 AR 124163A2 AR P210103281 A ARP210103281 A AR P210103281A AR P210103281 A ARP210103281 A AR P210103281A AR 124163 A2 AR124163 A2 AR 124163A2
- Authority
- AR
- Argentina
- Prior art keywords
- aripiprazole
- lyophilized
- composition
- water
- present
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 8
- 229960004372 aripiprazole Drugs 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000843 powder Substances 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un objeto de la presente invención consiste en proveer una composición de aripiprazol liofilizada en polvo, que denota buena dispersabilidad y que se dispersa fácilmente en una suspensión homogénea cuando se reconstituye con agua. La presente invención provee una composición de aripiprazol liofilizada obtenida mediante un proceso que comprende los pasos de pulverización, con el fin de congelar una suspensión de aripiprazol que contiene (I) aripiprazol, (II) un vehículo para el aripiprazol y (III) agua para inyección, y secado, que comprende aripiprazol y un vehículo para el aripiprazol y está en forma de un polvo, siendo las partículas del polvo esféricas y porosas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494088P | 2011-06-07 | 2011-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124163A2 true AR124163A2 (es) | 2023-02-22 |
Family
ID=46420491
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101990A AR086682A1 (es) | 2011-06-07 | 2012-06-06 | Formulacion de aripiprazol liofilizado |
| ARP210103281A AR124163A2 (es) | 2011-06-07 | 2021-11-29 | Una composición de aripiprazol liofilizada |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101990A AR086682A1 (es) | 2011-06-07 | 2012-06-06 | Formulacion de aripiprazol liofilizado |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11154507B2 (es) |
| EP (1) | EP2717859B1 (es) |
| JP (1) | JP6012637B2 (es) |
| KR (1) | KR102014124B1 (es) |
| CN (3) | CN103596557A (es) |
| AR (2) | AR086682A1 (es) |
| AU (1) | AU2012267810B2 (es) |
| BR (1) | BR112013031459B1 (es) |
| CA (1) | CA2837693C (es) |
| CO (1) | CO6842019A2 (es) |
| CY (1) | CY1118561T1 (es) |
| DK (1) | DK2717859T3 (es) |
| EA (1) | EA023951B1 (es) |
| ES (1) | ES2599479T3 (es) |
| HK (1) | HK1191245A1 (es) |
| HR (1) | HRP20161357T1 (es) |
| HU (1) | HUE031723T2 (es) |
| IL (1) | IL229467A (es) |
| JO (1) | JO3410B1 (es) |
| LT (1) | LT2717859T (es) |
| MX (1) | MX354473B (es) |
| MY (1) | MY166052A (es) |
| PL (1) | PL2717859T3 (es) |
| PT (1) | PT2717859T (es) |
| SG (1) | SG195046A1 (es) |
| SI (1) | SI2717859T1 (es) |
| TW (1) | TWI519320B (es) |
| UA (1) | UA112186C2 (es) |
| WO (1) | WO2012169662A1 (es) |
| ZA (1) | ZA201308868B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| CN105663057A (zh) * | 2015-12-30 | 2016-06-15 | 中国药科大学 | 阿立哌唑长效混悬剂及其制备方法 |
| CA3030972A1 (en) | 2016-07-28 | 2018-02-01 | Mylan Laboratories Ltd | Process for preparing sterile aripiprazole formulation |
| CN115768407A (zh) * | 2020-05-21 | 2023-03-07 | 江苏先声药业有限公司 | 一种含依匹哌唑药物组合物及其制备方法 |
| CN112656767A (zh) * | 2021-01-22 | 2021-04-16 | 烟台东诚药业集团股份有限公司 | 一种依诺肝素钠注射制剂及其制备方法 |
| EP4043008A1 (en) | 2021-02-15 | 2022-08-17 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Method for the preparation of a pharmaceutical composition comprising aripiprazole |
| WO2023083212A1 (zh) * | 2021-11-10 | 2023-05-19 | 广东东阳光药业有限公司 | 一种喹啉类药物的组合物 |
| GR1010656B (el) * | 2023-03-23 | 2024-03-21 | Φαρματεν Α.Β.Ε.Ε., | Φαρμακευτικο σκευασμα που περιλαμβανει εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| GB9105705D0 (en) | 1991-03-18 | 1991-05-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| ES2236700T3 (es) | 1993-11-19 | 2005-07-16 | Janssen Pharmaceutica N.V. | 1,2-benzazoles microencapsulados. |
| GB9718986D0 (en) | 1997-09-09 | 1997-11-12 | Danbiosyst Uk | Controlled release microsphere delivery system |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050019607A1 (en) | 2003-06-30 | 2005-01-27 | Franky So | OLED device with mixed emissive layer |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| WO2005041937A2 (en) * | 2003-10-23 | 2005-05-12 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile injectable aripiprazole formulation and method |
| EP1732107A4 (en) | 2004-03-30 | 2009-05-13 | Fujitsu Microelectronics Ltd | METHOD FOR CORRECTING EXPOSURE DATA TO AN ELECTRON BEAM |
| US7731873B2 (en) | 2005-08-09 | 2010-06-08 | Coopervision International Holding Company, Lp | Contact lens mold assemblies and systems and methods of producing same |
| JP2009508859A (ja) * | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アリピプラゾール製剤 |
| HUE036214T2 (hu) * | 2007-07-31 | 2018-06-28 | Otsuka Pharma Co Ltd | Eljárások aripiprazol-szuszpenzió és fagyasztva szárított készítmény elõállítására |
-
2012
- 2012-06-03 JO JOP/2012/0141A patent/JO3410B1/ar active
- 2012-06-06 AR ARP120101990A patent/AR086682A1/es not_active Application Discontinuation
- 2012-06-06 TW TW101120275A patent/TWI519320B/zh active
- 2012-06-07 HU HUE12731189A patent/HUE031723T2/hu unknown
- 2012-06-07 BR BR112013031459-1A patent/BR112013031459B1/pt active IP Right Grant
- 2012-06-07 US US14/124,459 patent/US11154507B2/en active Active
- 2012-06-07 CN CN201280027909.5A patent/CN103596557A/zh active Pending
- 2012-06-07 DK DK12731189.2T patent/DK2717859T3/en active
- 2012-06-07 JP JP2013554727A patent/JP6012637B2/ja active Active
- 2012-06-07 EP EP12731189.2A patent/EP2717859B1/en active Active
- 2012-06-07 CN CN201810450421.2A patent/CN108379231A/zh active Pending
- 2012-06-07 EA EA201391818A patent/EA023951B1/ru not_active IP Right Cessation
- 2012-06-07 WO PCT/JP2012/065180 patent/WO2012169662A1/en active Application Filing
- 2012-06-07 LT LTEP12731189.2T patent/LT2717859T/lt unknown
- 2012-06-07 PL PL12731189T patent/PL2717859T3/pl unknown
- 2012-06-07 MX MX2013014186A patent/MX354473B/es active IP Right Grant
- 2012-06-07 AU AU2012267810A patent/AU2012267810B2/en active Active
- 2012-06-07 ES ES12731189.2T patent/ES2599479T3/es active Active
- 2012-06-07 CN CN201610937357.1A patent/CN106389357A/zh active Pending
- 2012-06-07 SI SI201230741A patent/SI2717859T1/sl unknown
- 2012-06-07 MY MYPI2013702194A patent/MY166052A/en unknown
- 2012-06-07 SG SG2013085568A patent/SG195046A1/en unknown
- 2012-06-07 CA CA2837693A patent/CA2837693C/en active Active
- 2012-06-07 PT PT127311892T patent/PT2717859T/pt unknown
- 2012-06-07 KR KR1020147000021A patent/KR102014124B1/ko active IP Right Grant
- 2012-07-06 UA UAA201315553A patent/UA112186C2/uk unknown
-
2013
- 2013-11-17 IL IL229467A patent/IL229467A/en active IP Right Grant
- 2013-11-19 ZA ZA2013/08868A patent/ZA201308868B/en unknown
- 2013-12-30 CO CO13302836A patent/CO6842019A2/es unknown
-
2014
- 2014-05-14 HK HK14104543.8A patent/HK1191245A1/zh unknown
-
2016
- 2016-10-18 HR HRP20161357TT patent/HRP20161357T1/hr unknown
- 2016-11-03 CY CY20161101125T patent/CY1118561T1/el unknown
-
2021
- 2021-09-24 US US17/448,862 patent/US20220008341A1/en not_active Abandoned
- 2021-11-29 AR ARP210103281A patent/AR124163A2/es unknown
-
2023
- 2023-10-09 US US18/483,098 patent/US20240041774A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124163A2 (es) | Una composición de aripiprazol liofilizada | |
| BR112014014323A2 (pt) | uso de excipientes poliméricos para liofilização ou congelamento de partículas | |
| CL2014002220A1 (es) | Compuesto 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido[2,3-d]pirimidin-6-il)fenil)urea, inhibidor de la cinasa raf; forma cristalina del compuesto; composicion farmaceutica que lo comprende; y metodo para tratar el cancer. | |
| BR112015004418A2 (pt) | composição de pó seco inalável, sistema de liberação de fármaco, processo para formar uma partícula e kit. | |
| BR112015022855A2 (pt) | composições e método para produção de um anticorpo in vitro | |
| MX2015006935A (es) | Bolsa soluble que comprende un tinte tonalizador. | |
| MX2015001958A (es) | Composiciones mejoradas de particulas substancialmente esfericas. | |
| BR112014029026A2 (pt) | partículas híbridas de carbono de superfície modificada, métodos de produção e aplicações das mesmas | |
| WO2012140274A3 (en) | Agonists and antagonists of the wnt pathway | |
| WO2014047486A3 (en) | Spray drying microcapsules | |
| CL2017001836A1 (es) | Una composición fertilizante y el método de su uso. | |
| CL2011001296A1 (es) | Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales. | |
| MX346518B (es) | Metodos de desarrollo de variantes de terpeno sintasa. | |
| BR112013028449A2 (pt) | composições compreendendo partículas de hidrogel | |
| WO2014199352A3 (en) | Lipid-based platinum-n-heterocyclic carbene compounds and nanoparticles | |
| MX2013008062A (es) | Seleccion de microcolonias encapsuladas en gel. | |
| PH12015500900A1 (en) | A stabilized pemetrexed formulation | |
| WO2014086982A3 (en) | Stable metal compounds, their compositions and methods of their use | |
| SMT201500320B (it) | Liofilizzazione di agente tensioattivo polmonare liposomale sintetico | |
| UY33308A (es) | Produccion de composiciones unificadas de alta densidad | |
| MX2015008302A (es) | Composiciones de arena para animales recubiertas de baja densidad. | |
| EP2931311A4 (en) | LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES | |
| IL229176B (en) | Cryopreserved, thawed and reactivated t cell containing compositions, methods of producing same and use of same in immunotherapy” | |
| MX2012008649A (es) | Uso de polietilenimidas como aditivo en suspensiones acuosas de materiales que contienen carbonato calcico. | |
| MX2015014701A (es) | Circuito genomico del receptor de vitamina d/smad que regula la compuerta de la respuesta fibrotica. |